Information on EC 1.1.1.B40 - 11beta-hydroxysteroid dehydrogenase (NAD+)

for references in articles please use BRENDA:EC1.1.1.B40
Word Map on EC 1.1.1.B40
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
1.1.1.B40
preliminary BRENDA-supplied EC number
RECOMMENDED NAME
GeneOntology No.
11beta-hydroxysteroid dehydrogenase (NAD+)
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
an 11beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
redox reaction
-
-
reduction
-
-
SYSTEMATIC NAME
IUBMB Comments
11beta-hydroxysteroid:NAD+ 11-oxidoreductase
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
gene 11beta-HSDsf, enzyme short form; Japanese eel, gene 11beta-HSDsf
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
type 2 enzyme
-
-
Manually annotated by BRENDA team
isozyme 11beta-HSD1; isozyme 11beta-HSD1
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Ovis aries aries
sheep, isoform 11beta-HSD2
-
-
Manually annotated by BRENDA team
isozyme 11beta-HSD2
-
-
Manually annotated by BRENDA team
isoform 11beta-HSD2
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
show the reaction diagram
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
show the reaction diagram
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH
show the reaction diagram
-
-
-
?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
show the reaction diagram
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
show the reaction diagram
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
-
ir
7-oxocholesterol + NADPH
7alpha-hydroxycholesterol + NADP+
show the reaction diagram
isozyme 11beta-HSD1, stereospecific reaction
-
-
?
7-oxocholesterol + NADPH
7beta-hydroxycholesterol + NADP+
show the reaction diagram
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
show the reaction diagram
corticosterone + NAD+
11-dehydrocorticosterone + NADH
show the reaction diagram
cortisol + beta-NAD+
cortisone + beta-NADH
show the reaction diagram
cortisol + NAD+
cortisone + NADH
show the reaction diagram
cortisol + NAD+
cortisone + NADH + H+
show the reaction diagram
cortisone + beta-NADPH
cortisol + beta-NADP+
show the reaction diagram
cortisone + NADPH
cortisol + NADP+
show the reaction diagram
dexamethasone + NAD+
11-dehydromethasone + NADH
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
show the reaction diagram
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
show the reaction diagram
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
show the reaction diagram
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH
show the reaction diagram
Q05KC1
-
-
-
?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
show the reaction diagram
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
show the reaction diagram
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
-
ir
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
show the reaction diagram
corticosterone + NAD+
11-dehydrocorticosterone + NADH
show the reaction diagram
cortisol + beta-NAD+
cortisone + beta-NADH
show the reaction diagram
cortisol + NAD+
cortisone + NADH
show the reaction diagram
cortisone + NADPH
cortisol + NADP+
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
NADP+
NADPH
additional information
-
NADH, no substrate affinity
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-gossypol
(+/-)-gossypol
(-)-gossypol
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
-
-
(2S)-5-(acetyloxy)-2-hydroxypentyl acetate
-
-
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid
-
-
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
-
-
(3beta)-3-hydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione
-
IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-3-hydroxyandrost-5-en-17-one
-
treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression
(3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid
-
IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
-
IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
-
-
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
-
-
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
-
-
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
-
IC50 value for isoform 11beta-HSD1 above 40 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
11-Dehydrocorticosterone
-
inhibition of isozyme 11beta-HSD2
11-dehydrocortisterone
-
-
11-deoxycorticosterone
11-oxo-3beta,5alpha-tetrathydrotestosterone
-
-
11-oxo-allopregnanolone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
11-oxo-progesterone
-
-
11-oxo-testosterone
-
-
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
-
i.e. cortisol
11beta,21-dihydroxypregn-4-en-3,20-dione
-
11-beta-HSD2, 50% inhibition at 0.00001 mM
11beta-hydroxy-allopregnanolone
-
-
11beta-hydroxyandrostanediol
-
-
11beta-hydroxyandrostenedione
-
-
11beta-hydroxyprogesterone
-
-
11beta-hydroxytestosterone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
17beta-estradiol
-
decrease in isoform HSD2 protein in male, but not female, fetal lung explant
18beta-glycyrrhetinic acid
-
inhibits both 11beta-HSD1 and 11beta-HSD2, but preferentially inhibits 11beta-HSD2
2'-hydroxyflavanone
2-oxopentane-1,5-diyl diacetate
3,11-dioxoolean-12-en-30-oic acid
-
-
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
-
IC50 in the presence of NADP+: 0.12 mM, IC50 in the presence of NAD+: 5.6 mM; i.e. CHAPS
3alpha,5alpha-tetrahydro-11-dehydrocorticosterone
-
-
3alpha,5alpha-tetrahydro-dehydrocortisterone
-
-
3alpha,5alpha-tetrahydroaldosterone
-
-
3alpha,5alpha-tetrahydrocorticosterone
-
inhibition of isozyme 11beta-HSD1 and isozyme isozyme 11beta-HSD2
3alpha,5alpha-tetrahydrocortisol
-
-
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
4-n-octylphenol
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0235 mM
4-nonylphenol
-
inhibition of liver isozyme 11beta-HSD1 and kidney isozyme 11beta-HSD2, 11beta-HSD1 IC50: 49.3 mM, isozyme 11beta-HSD2 IC50: 0.0203 mM
4-pregnen-11,17-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
4-pregnen-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.0001 mM
4-pregnen-11beta-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00005 mM
4-pregnen-16alpha-ol-3,20-dione
Ovis aries aries
-
not inhibitory
4-pregnen-17,21-diol-3,20-dione
Ovis aries aries
-
not inhibitory
4-pregnen-17alpha,20alpha-diol-3-one
Ovis aries aries
-
not inhibitory
4-pregnen-17alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.047 mM
4-pregnen-20alpha-ol-3-one
Ovis aries aries
-
IC50: 0.007 mM
4-pregnen-20beta-ol-3-one
Ovis aries aries
-
IC50: 0.008 mM
4-pregnen-21-ol-3,20-dione
Ovis aries aries
-
IC50: 0.001 mM
4-pregnen-3,11,20-trione
Ovis aries aries
-
IC50: 0.0004 mM
4-pregnen-3,20-dione
Ovis aries aries
-
IC50: 0.0011 mM
4-t-octylphenol
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0089 mM
5-hydroxy-4-oxopentyl acetate
5-pregnen-3beta,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.0001 mM
5alpha-dihydrocorticosterone
-
-
5alpha-pregnan-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
5alpha-pregnan-11beta,17alpha,21-triol-3,20-dione
Ovis aries aries
-
IC50: 0.0031 mM
5alpha-pregnan-11beta,21-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00015 mM
5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
Ovis aries aries
-
IC50: 0.008 mM
5alpha-pregnan-3alpha,11beta,21-triol-20-one
Ovis aries aries
-
IC50: 0.00026 mM
5alpha-pregnan-3alpha,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.00012 mM
5alpha-pregnan-3alpha,17alpha,21-triol-11,20-dione
Ovis aries aries
-
IC50: 0.0055 mM
5alpha-pregnan-3alpha,21-diol-11,20-dione
Ovis aries aries
-
IC50: 0.0008 mM
5alpha-Pregnan-3alpha,21-diol-20-one
Ovis aries aries
-
IC50: 0.0024 mM
5alpha-pregnan-3alpha-ol-20-one
Ovis aries aries
-
IC50: 0.008 mM
5beta-pregnan-3alpha,11alpha-diol-20-one
Ovis aries aries
-
not inhibitory
5beta-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
Ovis aries aries
-
not inhibitory
5beta-pregnan-3alpha,11beta,21-triol-20-one
Ovis aries aries
-
not inhibitory
5beta-pregnan-3alpha,11beta-diol-20-one
Ovis aries aries
-
not inhibitory
5beta-Pregnan-3alpha,21-diol-20-one
Ovis aries aries
-
not inhibitory
5beta-Pregnan-3alpha-ol-20-one
Ovis aries aries
-
not inhibitory
A23187
-
inhibits isozyme 11beta-HSD2 strongly
abietic acid
adamantyl triazole
-
adamantyl triazoles
-
aldosterone
BVT-14225
-
isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2
carbenoxolone
Cd2+
-
the ERK1/2 inhibitor U0126 can block cadmium-induced inhibition of placental 11beta-HSD2. Cadmium does not alter activities of p38 MAPK, JNK, or PI3 kinase. Cadmium specifically activates the ERK1/2 signaling pathway in human trophoblast cells
chenodeoxycholic acid
cholic acid
-
IC50: 3.529 mM
curcumin
-
inhibitory against isoform 11beta-HSD2 in intact cells with IC50 value of 14.56 microM
dexamethasone
-
-
di-n-butyl phthalate
di-n-octyl phthalate
di-n-pentyl phthalate
dicyclohexyl phthalate
diethyl phthalate
dipropyl phthalate
end-products
-
inhibition at high levels
-
estradiol
-
50% inhibition, DTT protects at 10 mM, estradiol has a regulatory function on the isozymes in the liver
Ethacrynic acid
-
IC50: 0.452 mM
flavanone
forskolin
-
slight inhibitory effect in absence of interleukin-1beta
Furosemide
-
IC50: 0.059 mM, competitive
glycyrrhetinic acid
glycyrrhizinic acid
-
-
glycyrrhizininc acid
-
-
interleukin-1beta
-
inhibits isozyme 11beta-HSD2, forskolin acts antagonistically strongly
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
mono (2-ethylhexyl) phthalate
mono-(2-ethylhexyl) phthalate
-
mono-(2-ethylhexyl) phthalate inhibits mRNA level and enzyme activity of 11beta-HSD2 in LbetaT2 cells at 0.0001 mM
n-alkyl-substituted adamantyl triazoles
-
NADP+
-
50% inhibition at 220 nmol
naringenin
-
IC50: 0.336 mM
naringin
-
IC50: 2.373 mM
Nifed
-
inhibits isozyme 11beta-HSD2 slightly
perfluorooctane sulfonate
Phenylbutazone
-
IC50: 1.358 mM
progesterone
sistosterol
-
IC50: 1.395 mM
SQ-22536
-
inhibits isozyme 11beta-HSD2
sterenin A
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin B
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin C
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin D
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
stigmasterol
-
IC50: 1.968 mM
T0504
tributyltin
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0165 mM
Triphenyltin
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0033 mM
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
17alpha,20beta-dihydroxy-4-pregnen-3-one
activates in immature testis
dexamethasone
-
after application of dexamethasone, 11beta-HSD1 mRNA increases in muscle of both diabetic and control subjects, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group
prostaglandin E2
-
stimulation of progesterone production and of 11beta-hydroxysteroid dehydrogenase activity via the prostaglandin E receptor 2-cAMP signalling pathway in luteinizing granulosa cells
U0126
-
the ERK1/2 inhibitor activates 11beta-HSD2 enzyme activity 3fold
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00038 - 0.00085
11-Dehydrocorticosterone
0.000047 - 0.008
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
0.0000051 - 0.00108
11beta,21-dihydroxypregn-4-en-3,20-dione
0.00089
17,21-dihydroxy-pregn-4-ene-3,11,20-trione
-
i.e. cortisone, temperature not specified in the publication, pH 5.5-6
0.0022
21-hydroxy-pregn-4-en-3,11,20-trione
-
temperature not specified in the publication, pH 5.5-6
0.000047 - 0.00028
corticosterone
0.000154 - 0.00136
cortisol
0.00052 - 0.00157
cortisone
0.0000044 - 0.091
NAD+
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.002 - 0.2
2'-hydroxyflavanone
0.0021 - 0.011
abietic acid
0.00011 - 0.00094
carbenoxolone
0.00055 - 0.035
chenodeoxycholic acid
0.0012 - 0.2
flavanone
0.000028 - 0.00044
glycyrrhetinic acid
0.0018
progesterone
-
probably minimal physiological importance
0.000006 - 0.0018
T0504
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00061 - 0.00105
(+)-gossypol
0.00088 - 0.00105
(+/-)-gossypol
0.00133 - 0.0019
(-)-gossypol
0.0000049
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
0.00075
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
0.0000029
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
Homo sapiens
-
pH 7.4, 37C
0.000122
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
Homo sapiens
-
pH not specified in the publication, 37C
0.000458
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
0.0000611
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37C
0.0000029
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37C
0.00213
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37C
0.0000145
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
0.000268
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
0.0000069
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
Homo sapiens
-
pH 7.4, 37C
0.00047
11-dehydrocortisterone
Ovis aries
-
pH 8.4, 37C
0.001
11-deoxycorticosterone
Ovis aries aries
-
IC50: 0.001 mM
0.008
11-oxo-3beta,5alpha-tetrathydrotestosterone
Ovis aries
-
pH 8.4, 37C
0.0015
11-oxo-allopregnanolone
Ovis aries
-
pH 8.4, 37C
0.0004
11-oxo-progesterone
Ovis aries
-
pH 8.4, 37C
0.00135
11-oxo-testosterone
Ovis aries
-
pH 8.4, 37C
0.000061
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
Homo sapiens
-
i.e. cortisol, pH and temperature not specified in the publication
0.0000051
11beta,21-dihydroxypregn-4-en-3,20-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00012
11beta-hydroxy-allopregnanolone
Ovis aries
-
pH 8.4, 37C
0.0045
11beta-hydroxyandrostanediol
Ovis aries
-
pH 8.4, 37C
0.0078
11beta-hydroxyandrostenedione
Ovis aries
-
pH 8.4, 37C
0.00005
11beta-hydroxyprogesterone
Ovis aries
-
pH 8.4, 37C
0.00035
11beta-hydroxytestosterone
Ovis aries
-
pH 8.4, 37C
0.000257
18beta-glycyrrhetinic acid
Homo sapiens
-
37C, pH not specified in the publication
0.000329
3,11-dioxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37C
5.6
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
3alpha,5alpha-tetrahydro-dehydrocortisterone
Ovis aries
-
pH 8.4, 37C
0.0005
3alpha,5alpha-tetrahydroaldosterone
Ovis aries
-
pH 8.4, 37C
0.00026
3alpha,5alpha-tetrahydrocorticosterone
Ovis aries
-
pH 8.4, 37C
0.008
3alpha,5alpha-tetrahydrocortisol
Ovis aries
-
pH 8.4, 37C
0.000097 - 0.254
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
0.0235
4-n-octylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37C
0.0203
4-nonylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37C
0.00035
4-pregnen-11,17-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
0.0001
4-pregnen-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.0001 mM
0.00005
4-pregnen-11beta-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00005 mM
0.047
4-pregnen-17alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.047 mM
0.007
4-pregnen-20alpha-ol-3-one
Ovis aries aries
-
IC50: 0.007 mM
0.008
4-pregnen-20beta-ol-3-one
Ovis aries aries
-
IC50: 0.008 mM
0.001
4-pregnen-21-ol-3,20-dione
Ovis aries aries
-
IC50: 0.001 mM
0.0004
4-pregnen-3,11,20-trione
Ovis aries aries
-
IC50: 0.0004 mM
0.0011
4-pregnen-3,20-dione
Ovis aries aries
-
IC50: 0.0011 mM
0.0089
4-t-octylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37C
0.0001
5-pregnen-3beta,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.0001 mM
0.00015
5alpha-dihydrocorticosterone
Ovis aries
-
pH 8.4, 37C
0.00035
5alpha-pregnan-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
0.0031
5alpha-pregnan-11beta,17alpha,21-triol-3,20-dione
Ovis aries aries
-
IC50: 0.0031 mM
0.00015
5alpha-pregnan-11beta,21-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00015 mM
0.008
5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
Ovis aries aries
-
IC50: 0.008 mM
0.00026
5alpha-pregnan-3alpha,11beta,21-triol-20-one
Ovis aries aries
-
IC50: 0.00026 mM
0.00012
5alpha-pregnan-3alpha,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.00012 mM
0.0055
5alpha-pregnan-3alpha,17alpha,21-triol-11,20-dione
Ovis aries aries
-
IC50: 0.0055 mM
0.0008
5alpha-pregnan-3alpha,21-diol-11,20-dione
Ovis aries aries
-
IC50: 0.0008 mM
0.0024
5alpha-Pregnan-3alpha,21-diol-20-one
Ovis aries aries
-
IC50: 0.0024 mM
0.008
5alpha-pregnan-3alpha-ol-20-one
Ovis aries aries
-
IC50: 0.008 mM
0.00002 - 0.00005
carbenoxolone
0.513
chenodeoxycholic acid
Cavia porcellus
-
IC50: 0.513 mM
3.529
cholic acid
Cavia porcellus
-
IC50: 3.529 mM
0.0089
dexamethasone
Homo sapiens
-
pH and temperature not specified in the publication
0.01369
di-n-butyl phthalate
Rattus norvegicus
-
-
0.03264 - 0.0465
dicyclohexyl phthalate
0.08559
dipropyl phthalate
Rattus norvegicus
-
-
0.452
Ethacrynic acid
Cavia porcellus
-
IC50: 0.452 mM
0.059
Furosemide
Cavia porcellus
-
IC50: 0.059 mM, competitive
0.0000024 - 0.000257
glycyrrhetinic acid
0.00000071
glycyrrhizinic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000071
glycyrrhizininc acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.1108 - 0.1218
mono (2-ethylhexyl) phthalate
0.0168 - 0.3279
mono-(2-ethylhexyl) phthalate
0.336
naringenin
Cavia porcellus
-
IC50: 0.336 mM
2.373
naringin
Cavia porcellus
-
IC50: 2.373 mM
0.000048 - 0.000293
perfluorooctane sulfonate
1.358
Phenylbutazone
Cavia porcellus
-
IC50: 1.358 mM
1.395
sistosterol
Cavia porcellus
-
IC50: 1.395 mM
0.01
sterenin A
Homo sapiens
-
value above, pH not specified in the publication, 26C
0.01
sterenin B
Homo sapiens
-
value above, pH not specified in the publication, 26C
0.01
sterenin C
Homo sapiens
-
value above, pH not specified in the publication, 26C
0.01
sterenin D
Homo sapiens
-
value above, pH not specified in the publication, 26C
1.968
stigmasterol
Cavia porcellus
-
IC50: 1.968 mM
0.0165
tributyltin
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37C
0.0033
Triphenyltin
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37C
additional information
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5 - 6
-
oxidase activity
8.4
-
assay at
9
-
oxidase activity
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 10
-
11-dehydrogenase activity, broad range of pH optimum
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
-
assay at room temperature
26
-
assay at
28
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
rectum, sigmoid colon
Manually annotated by BRENDA team
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
Manually annotated by BRENDA team
-
aldosterone-sensitive, NAD+ specificity
Manually annotated by BRENDA team
-
presence of 11beta-hydroxysteroid dehydrogenase mRNA transcripts and protein in all tissues of the reproductive tract examined, but cortison-cortisol interconversion is undetectable in the corpus and cauda epididymides, vas deferens, vesicular and prostate glands
Manually annotated by BRENDA team
-
expression of mRNA for 11beta-hydroxysteroid dehydrogenase type 1, 11beta-hydroxysteroid dehydrogenase type 2 and for glucocorticoid receptor during the estrous cycle. Level of 11beta-hydroxysteroid dehydrogenase type 1 mRNA is higher at the regressed state than at the other stages, whereas level of 11beta-hydroxysteroid dehydrogenase type 2 mRNA is lower at the regressed stage than at the other stages
Manually annotated by BRENDA team
-
epithelium
Manually annotated by BRENDA team
-
of normotensive and hypertensive rats, the latter are hyperthrophied and fibrotic and have structural alterations in the coronary circulation, expression of isozymes 11beta-HSD1 and 11beta-HSD2, overview
Manually annotated by BRENDA team
-
11beta-HSD2, but not 11beta-HSD1, is strongly expressed in LbetaT2 cells
Manually annotated by BRENDA team
-
of neonatal pig. High expression of 11beta-hydroxysteroid dehydrogenase type 2 mRNA, resulting in oxidation from cortisol to cortison, with no detection of the reduction reaction. Activity of type 2 enzyme is higher than the oxidation activity of the type 1 enzyme
Manually annotated by BRENDA team
-
peripheral lymph nodes and mesenteric lymph nodes
Manually annotated by BRENDA team
-
lung epithelial cell line, isozymes HSD1 and HSD2
Manually annotated by BRENDA team
-
expression and activity of isozyme 11beta-HSD2 in probes of seven different women with ovarian cancer of different types, overview
Manually annotated by BRENDA team
-
high level of expression and activity
Manually annotated by BRENDA team
-
highly expressed
Manually annotated by BRENDA team
-
renal cortical collecting duct cell line
Manually annotated by BRENDA team
-
mainly isozyme 11beta-HSD2, the concentration of isozyme 11beta-HSD1 is 10-100fold lower, expression analysis, isozyme 11beta-HSD2 shows strong expression and activity in quiescent cells
Manually annotated by BRENDA team
-
at baseline, mRNA levels are similar in diabetic and control sugjects for 11beta-HSD1, 11beta-HSD2, and hexose-6-phosphate dehydrogenase. 11beta-HSD1 activity is reduced in diabetic subjects, while 11beta-HSD2 activity is increased. After application of dexamethasone, 11beta-HSD1 mRNA increases in both groups, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group; mRNA levels are similar in diabetic and control subjects for 11beta-hydroxysteroid dehydrogenase 1 and 11beta-hydroxysteroid dehydrogenase 2. 11beta-Hydroxysteroid dehydrogenase 2-activity is higher in diabetic patients. After treatment with dexamethasone, 11beta-hydroxysteroid dehydrogenase 1-mRNA increases in both groups, whereas 11beta-hydroxysteroid dehydrogenase 2-mRNA decreases. 11beta-Hydroxysteroid dehydrogenase 1-activity increases in diabetic patients, but not in control, whereas 11beta-hydroxysteroid dehydrogenase 2-activity does not change in either group
Manually annotated by BRENDA team
-
low levels of mRNA
Manually annotated by BRENDA team
-
placental trophoblast cells
Manually annotated by BRENDA team
-
isoform 11beta-HSD1 is clearly expressed while isoform 11beta-HSD2 is much less prominent, 11beta-HSD1 protein expression predominates in endothelial cells and varies during periods of growth
Manually annotated by BRENDA team
-
NAD+-dependent 11beta-hydroxysteroid dehydrogenase activity
Manually annotated by BRENDA team
-
splanchnic activity
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
isozyme 11beta-HSD2
Manually annotated by BRENDA team
additional information
-
subcellular localization of isozyme 11beta-HSD2, overview, isozyme 11beta-HSD2 activity and plasma corticosterone are determined in toads from pre- (PR), post- (P), and reproductive (R) periods, overview
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
32000
x * 32000, recombinant isozyme 11beta-HSD1, SDS-PAGE
36000
-
x * 36000, calculated
42000
-
11beta-HSD2, SDS-PAGE
44140
-
x * 44140, calculation from cDNA sequence